References
1. Zhou ES, Bhatia SK. Divergent Effects of COVID-19 Pandemic on Reported Adverse Events for Percutaneous Aortic Valve Prostheses and Non-Allograft Tissue Valves. Am J Cardiol. 2022 Mar 15;167:151-153.
2. Food and Drug Administration. MAUDE – Manufacturer and User Facility Device Experience. 2022. Available at:https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/Search.cfm?smc=1. Accessed May 15, 2022.
3. Ahamed J. Severe aortic stenosis patient risk during the COVID-19 pandemic. Open Heart. 2020 Sep;7(2):e001355.
4. Khialani B, MacCarthy P. Transcatheter management of severe aortic stenosis during the COVID-19 pandemic. Heart. 2020 Aug;106(15):1183-1190.
5. Ram E, Amunts S, Zuroff E, Peled Y, Kogan A, Raanani E, Sternik L. Outcomes of isolated surgical aortic valve replacement in the era of transcatheter aortic valve implantation. J Card Surg. 2020 Jul;35(7):1452-1457.